Clinical Trials at the Knight ADRC
What is a clinical trial?
A clinical trial is a research study in human volunteers to answer specific health questions. There are different kinds of clinical trials, including those to study prevention options, new drug treatments, or new diagnostic techniques. Many clinical trials are done to see if a new drug or device is safe and effective for people to use. It is important to test drugs and medical products in the people they are meant to help. Some people participate in clinical trials because they have exhausted standard (approved) treatment options. Other people participate in trials because they want to contribute to the advancement of medical knowledge. For each clinical trial, researchers develop eligibility criteria. Not everyone who applies for a clinical trial will be accepted. Anyone considering a clinical trial should know that there are benefits and risks associated with participating, and should discuss the protocol of the trial and the benefits and risks before consenting to participate. --Adapted from the US Food and Drug Administration’s “Basic Questions and Answers about Clinical Trials”
Below is a list of clinical trials being conducted at the Knight ADRC along with some basic information about each trial. Check this page regularly as new trials may be added to the list. If you don't meet eligibility requirements, consider enrolling in our non-clinical, observational research study by visiting the Memory & Aging Project page.
The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU)
Autosomal Dominant Alzheimer’s Disease (ADAD) is a rare form of Alzheimer’s that causes memory loss and dementia in people in their 30s to 50s.
The Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) at Washington University has launched the first prevention trial for ADAD families. The DIAN-TU trial focuses on drugs that could potentially change the course of the disease. The trial’s goal is to determine the safety, tolerability, and effectiveness of these drugs. The DIAN-TU trial will determine if these medications can prevent, delay, or possibly even reverse Alzheimer’s disease changes in the brain.
Although there are differences between ADAD and the more common age-associated, sporadic Alzheimer’s disease, the results of this study will have implications for future studies and treatments in sporadic Alzheimer's disease.
Are you eligible to participate?
Does your family have an ADAD mutation (PSEN1, PSEN2, or APP) for early onset Alzheimer's disease (less than 60 years) in multiple generations?
Are you cognitively normal, or do you have mild dementia?
Are you between the ages of 18 to 80?
Are you between 15 years younger to 10 years older than your parent was when they first showed the signs of Alzheimer’s disease?
Do you have a family member or friend that can accompany you to visits and provide information about your medical history?
If you answered YES to ALL the above questions, you may be eligible to participate.
For more information